ArticleThe Journal of biological chemistry2009
Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.
Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 65 citations in OpenAlex.
- In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans.American journal of physiology. Regulatory, integrative and comparative physiology · 2016Trial
- Aminopeptidase M17 in bacteria: insights into structure, function, and potential as a drug target.Journal of bacteriology · 2026Review
- Structural Identification and Molecular Interaction Modeling Analysis of Antioxidant Activity Selenium-Enriched Peptides from Selenium-EnrichedAntioxidants (Basel, Switzerland) · 2025Article
- Structural basis of neuropeptide Y signaling through YMedComm · 2024Article
- Topical Neuropeptide Y for Ischemic Skin Wounds.International journal of molecular sciences · 2024Article
- Detection of endogenous NPY release determined by novel GRAB sensor in cultured cortical neurons.Frontiers in cellular neuroscience · 2023Article
- 6-(Arylaminomethyl) Isoquinolines as Enzyme Inhibitors and Their Preparation: A Patent Highlight of Factor XIIa Inhibitors.Cardiovascular & hematological agents in medicinal chemistry · 2023Article
- The identification of two M20B family peptidases required for full virulence inFrontiers in cellular and infection microbiology · 2023Article
- Ultrasensitive and Cost-Effective Detection of Neuropeptide-Y by a Disposable Immunosensor: A New Functionalization Route for Indium-Tin Oxide Surface.Biosensors · 2022Article
- Biomarkers and Detection Platforms for Human Health and Performance Monitoring: A Review.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Peptides: When Is the Assessment of Certain Factors Warranted?Antibodies (Basel, Switzerland) · 2021Review
- Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice.Scientific reports · 2021Article
- Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS.Analytical chemistry · 2020Article
- Angiotensin-Converting Enzyme Inhibitor Protects Against Cisplatin Nephrotoxicity by Modulating Kinin B1 Receptor Expression and Aminopeptidase P Activity in Mice.Frontiers in molecular biosciences · 2020Article
- NPY and Gene Therapy for Epilepsy: How, When,... and Y.Frontiers in molecular neuroscience · 2020Review
- Expression of neuropeptide Y is increased in an activated human HSC cell line.Scientific reports · 2019Article
- Placental Neuropeptide Y ( NPY) and NPY receptors expressions and serum NPY levels in preeclampsia.Experimental biology and medicine (Maywood, N.J.) · 2019Article
- Identification of novel loci affecting circulating chromogranins and related peptides.Human molecular genetics · 2017Article
- The anorexic hormone Peptide YY3-36 is rapidly metabolized to inactive Peptide YY3-34 in vivo.Physiological reports · 2015Article
- The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour.Acta physiologica (Oxford, England) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is little information on how neuropeptide Y (NPY) proteolysis by peptidases occurs in serum, in part because reliable techniques are lacking to distinguish different NPY immunoreactive forms and also because the factors affecting the expression of these enzymes have been poorly studied. In the present study, LC-MS/MS was used to identify and quantify NPY fragments resulting from peptidolytic cleavage of NPY(1-36) upon incubation with human serum. Kinetic studies indicated that NPY(1-36) is rapidly cleaved in serum into 3 main fragments with the following order of efficacy: NPY(3-36) >> NPY(3-35) > NPY(2-36). Trace amounts of additional NPY forms were identified by accurate mass spectrometry. Specific inhibitors of dipeptidyl peptidase IV, kallikrein, and aminopeptidase P prevented the production of NPY(3-36), NPY(3-35), and NPY(2-36), respectively. Plasma kallikrein at physiological concentrations converted NPY(3-36) into NPY(3-35). Receptor binding assays revealed that NPY(3-35) is unable to bind to NPY Y1, Y2, and Y5 receptors; thus NPY(3-35) may represent the major metabolic clearance product of the Y2/Y5 agonist, NPY(3-36).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.